Operaciones Takeda Pharmaceutical Company Limited - 4502 CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 24.12 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.010938% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.011284% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | JPY | ||||||||
Margen | 20% | ||||||||
Mercado de valores | Japan | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 4252.6 |
Abrir* | 4228.56 |
Cambio de 1 año* | 17.37% |
Rango del día* | 4228.56 - 4266.86 |
Rango de 52 semanas | 3,455.00-4,478.00 |
Volumen medio (10 días) | 5.94M |
Volumen medio (3 meses) | 88.20M |
Capitalización de mercado | 6,745.33B |
Ratio P/E | 24.23 |
Acciones en circulación | 1.55B |
Ingresos | 3,944.61B |
EPS | 175.97 |
Dividendo (Rendimiento %) | 4.22238 |
Beta | 0.99 |
Próxima fecha de resultados | May 11, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 4254.99 | 11.77 | 0.28% | 4243.22 | 4267.86 | 4224.16 |
Mar 23, 2023 | 4252.60 | -32.31 | -0.75% | 4284.91 | 4286.90 | 4240.03 |
Mar 22, 2023 | 4358.72 | -55.75 | -1.26% | 4414.47 | 4414.47 | 4352.73 |
Mar 20, 2023 | 4283.82 | -61.23 | -1.41% | 4345.05 | 4347.74 | 4282.72 |
Mar 17, 2023 | 4369.09 | 34.51 | 0.80% | 4334.58 | 4382.66 | 4320.91 |
Mar 16, 2023 | 4273.94 | 6.88 | 0.16% | 4267.06 | 4292.79 | 4244.02 |
Mar 15, 2023 | 4332.19 | 30.12 | 0.70% | 4302.07 | 4332.19 | 4286.81 |
Mar 14, 2023 | 4265.46 | 32.02 | 0.76% | 4233.44 | 4293.29 | 4206.11 |
Mar 13, 2023 | 4279.92 | 5.49 | 0.13% | 4274.43 | 4290.30 | 4240.93 |
Mar 10, 2023 | 4335.78 | -9.97 | -0.23% | 4345.75 | 4354.23 | 4323.71 |
Mar 9, 2023 | 4388.64 | 54.76 | 1.26% | 4333.88 | 4390.64 | 4317.82 |
Mar 8, 2023 | 4323.81 | 31.92 | 0.74% | 4291.89 | 4329.90 | 4289.00 |
Mar 7, 2023 | 4289.10 | 19.16 | 0.45% | 4269.94 | 4292.89 | 4264.86 |
Mar 6, 2023 | 4260.97 | 21.94 | 0.52% | 4239.03 | 4269.45 | 4233.94 |
Mar 3, 2023 | 4237.04 | 46.28 | 1.10% | 4190.76 | 4252.40 | 4190.16 |
Mar 2, 2023 | 4172.11 | 5.49 | 0.13% | 4166.62 | 4188.56 | 4155.23 |
Mar 1, 2023 | 4165.22 | -5.09 | -0.12% | 4170.31 | 4191.16 | 4164.13 |
Feb 28, 2023 | 4195.54 | 28.22 | 0.68% | 4167.32 | 4201.53 | 4166.22 |
Feb 27, 2023 | 4186.07 | -13.37 | -0.32% | 4199.44 | 4211.11 | 4183.17 |
Feb 24, 2023 | 4186.07 | -49.07 | -1.16% | 4235.14 | 4235.14 | 4157.63 |
Takeda Pharmaceutical Company Limited Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
Ingresos | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
Coste de los ingresos, total | 1106850 | 994308 | 1089760 | 651729 | 495921 |
Beneficio bruto | 2462160 | 2203500 | 2201420 | 1445500 | 1274610 |
Gastos totales de explotación | 3123810 | 2596860 | 3193730 | 1874650 | 1531000 |
Gastos de venta/general/administración Gastos, total | 886361 | 875663 | 964737 | 717599 | 628106 |
Investigación y desarrollo | 526087 | 455833 | 492381 | 368298 | 325441 |
Depreciation / Amortization | 472915 | 421864 | 455420 | 178617 | 122131 |
Gastos (ingresos) extraordinarios | 100290 | -265230 | 189043 | -41201 | 28183 |
Other Operating Expenses, Total | 31309 | 114422 | 2384 | -2507 | -3907 |
Ingresos de explotación | 445198 | 600952 | 97459 | 222577 | 239528 |
Ingresos por intereses (gastos), netos No operativos | -142628 | -234717 | -158213 | -94965 | -22323 |
Otros, netos | 1 | ||||
Ingresos netos antes de impuestos | 302571 | 366235 | -60754 | 127612 | 217205 |
Ingresos netos después de impuestos | 230166 | 376171 | 44290 | 135080 | 186708 |
Intereses menores | -107 | -166 | -49 | 112 | 178 |
Beneficio neto antes de partidas extra. Elementos | 230059 | 376005 | 44241 | 135192 | 186886 |
Ingresos netos | 230059 | 376005 | 44241 | 135192 | 186886 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 230059 | 376005 | 44241 | 135192 | 186886 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 230059 | 376005 | 44241 | 135192 | 186886 |
Beneficio neto diluido | 230059 | 376005 | 44241 | 135192 | 186886 |
Promedio ponderado de acciones diluidas | 1577.17 | 1573.54 | 1566.2 | 966.897 | 786.69 |
BPA diluido sin partidas extraordinarias | 145.868 | 238.955 | 28.2473 | 139.82 | 237.56 |
Dividends per Share - Common Stock Primary Issue | 180 | 180 | 180 | 180 | 180 |
BPA normalizado diluido | 194.24 | 129.394 | 106.703 | 112.123 | 268.355 |
Gasto (ingreso) por intereses - Explotación neta | 2112 | -64872 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Ingresos totales | 873289 | 901294 | 844819 | 949603 | 770274 |
Ingresos | 873289 | 901294 | 844819 | 949603 | 770274 |
Coste de los ingresos, total | 308380 | 281404 | 275797 | 241264 | 253446 |
Beneficio bruto | 564909 | 619890 | 569022 | 708339 | 516828 |
Gastos totales de explotación | 874908 | 784810 | 747392 | 701051 | 619734 |
Gastos de venta/general/administración Gastos, total | 223429 | 231078 | 212011 | 219843 | 234388 |
Investigación y desarrollo | 143628 | 128378 | 131600 | 122480 | 113289 |
Depreciation / Amortization | 149283 | 118087 | 102721 | 102824 | 114294 |
Gastos (ingresos) extraordinarios | 33062 | 26767 | 27979 | 16751 | 29440 |
Other Operating Expenses, Total | 17126 | -904 | -2716 | -2111 | -125123 |
Ingresos de explotación | -1619 | 116484 | 97427 | 248552 | 150540 |
Ingresos por intereses (gastos), netos No operativos | -52429 | -44291 | -35980 | -25574 | -19662 |
Ingresos netos antes de impuestos | -54047 | 72193 | 61447 | 222978 | 130878 |
Ingresos netos después de impuestos | -11375 | 57820 | 45995 | 137726 | 197144 |
Intereses menores | 17 | -51 | -31 | -43 | -46 |
Beneficio neto antes de partidas extra. Elementos | -11358 | 57769 | 45964 | 137683 | 197098 |
Ingresos netos | -11358 | 57769 | 45964 | 137683 | 197098 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -11358 | 57770 | 45964 | 137684 | 197098 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -11358 | 57770 | 45964 | 137684 | 197098 |
Beneficio neto diluido | -11358 | 57770 | 45964 | 137684 | 197098 |
Promedio ponderado de acciones diluidas | 1553.81 | 1574.97 | 1580.42 | 1574.43 | 1574.48 |
BPA diluido sin partidas extraordinarias | -7.30976 | 36.68 | 29.0834 | 87.4503 | 125.183 |
Dividends per Share - Common Stock Primary Issue | 90 | 0 | 90 | 0 | 90 |
BPA normalizado diluido | 6.52092 | 50.2916 | 42.335 | 94.0219 | 137.337 |
Total Adjustments to Net Income | 1 | 0 | 1 | ||
Otros, netos | 1 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Activo Corriente | 2593640 | 2712890 | 2469430 | 2993040 | 1078810 |
Efectivo e inversiones a corto plazo | 875000 | 1002820 | 653436 | 725819 | 375186 |
Efectivo y Equivalentes | 389058 | 335027 | 188640 | 462890 | 243324 |
Inversiones a corto plazo | 485942 | 667793 | 464796 | 262929 | 131862 |
Total deudores, neto | 724377 | 812714 | 784921 | 749119 | 428792 |
Accounts Receivable - Trade, Net | 617518 | 707487 | 670708 | 657681 | 360833 |
Total Inventory | 853167 | 753881 | 759599 | 919670 | 212944 |
Other Current Assets, Total | 141098 | 143478 | 271476 | 598429 | 61886 |
Total Assets | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
Property/Plant/Equipment, Total - Net | 1582800 | 1453920 | 1386370 | 1331930 | 536801 |
Property/Plant/Equipment, Total - Gross | 2453010 | 2191740 | 2084120 | 1971520 | 1191400 |
Accumulated Depreciation, Total | -870208 | -737818 | -697754 | -639591 | -654597 |
Goodwill, Net | 4407750 | 4033920 | 4012530 | 4240250 | 1029250 |
Intangibles, Net | 3818540 | 3909110 | 4171360 | 4751170 | 1014260 |
Long Term Investments | 330133 | 348350 | 369455 | 299922 | 304385 |
Other Long Term Assets, Total | 445150 | 454110 | 411948 | 176463 | 142957 |
Total Current Liabilities | 2145730 | 1773180 | 2175900 | 2553050 | 737509 |
Accounts Payable | 295933 | 232105 | 211627 | 212348 | 133705 |
Notes Payable/Short Term Debt | 285 | 69 | 5014 | 500002 | 18 |
Current Port. of LT Debt/Capital Leases | 203708 | 22084 | 581803 | 484944 | |
Other Current Liabilities, Total | 1645800 | 1518920 | 1377450 | 1355760 | 603786 |
Total Liabilities | 7495000 | 7739260 | 8097610 | 8610790 | 2109040 |
Total Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
Deferred Income Tax | 473145 | 576542 | 765079 | 783356 | 90725 |
Minority Interest | 504 | 4140 | 4003 | 4006 | 19985 |
Other Liabilities, Total | 734202 | 772180 | 646144 | 504372 | 275176 |
Total Equity | 5683020 | 5173040 | 4723480 | 5181980 | 1997420 |
Common Stock | 1676260 | 1668140 | 1668120 | 1643580 | 77914 |
Additional Paid-In Capital | 1708870 | 1688420 | 1680290 | 1650230 | 90740 |
Retained Earnings (Accumulated Deficit) | 1479720 | 1509910 | 1369970 | 1595430 | 1557310 |
Treasury Stock - Common | -116007 | -59552 | -87463 | -57142 | -74373 |
Unrealized Gain (Loss) | 22068 | 41983 | 22891 | 46380 | 73037 |
Other Equity, Total | 912106 | 324131 | 69673 | 303499 | 272799 |
Total Liabilities & Shareholders’ Equity | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
Total Common Shares Outstanding | 1550.36 | 1563.36 | 1557.77 | 1554.78 | 781.309 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 2593640 | 2477890 | 2456350 | 2476460 | 2712890 |
Efectivo e inversiones a corto plazo | 875000 | 751896 | 633623 | 684850 | 1002820 |
Efectivo y Equivalentes | 849695 | 724341 | 607881 | 654920 | 966222 |
Inversiones a corto plazo | 25305 | 27555 | 25742 | 29930 | 36598 |
Total deudores, neto | 724377 | 756117 | 887295 | 858957 | 812714 |
Accounts Receivable - Trade, Net | 696644 | 715515 | 843625 | 827253 | 783091 |
Total Inventory | 853167 | 811324 | 783476 | 779148 | 753881 |
Other Current Assets, Total | 141098 | 158556 | 151959 | 153503 | 143478 |
Total Assets | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
Property/Plant/Equipment, Total - Net | 1582800 | 1493590 | 1459920 | 1452170 | 1453920 |
Goodwill, Net | 4407750 | 4167990 | 4078370 | 4058940 | 4033920 |
Intangibles, Net | 3818540 | 3791880 | 3783680 | 3856430 | 3909110 |
Long Term Investments | 330133 | 334812 | 352091 | 374659 | 348350 |
Other Long Term Assets, Total | 445150 | 432359 | 429864 | 438578 | 454110 |
Total Current Liabilities | 2145730 | 1809250 | 1918750 | 1706780 | 1773180 |
Accounts Payable | 516297 | 351185 | 336600 | 320645 | 343838 |
Notes Payable/Short Term Debt | 285 | 0 | 0 | 0 | 69 |
Current Port. of LT Debt/Capital Leases | 203708 | 122936 | 214886 | 24272 | 22084 |
Other Current Liabilities, Total | 1425440 | 1335130 | 1367260 | 1361860 | 1407180 |
Total Liabilities | 7495000 | 7367190 | 7236340 | 7418980 | 7739260 |
Total Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
Deferred Income Tax | 473145 | 589481 | 576738 | 578065 | 576542 |
Minority Interest | 504 | 493 | 426 | 385 | 4140 |
Other Liabilities, Total | 734202 | 736023 | 723951 | 752155 | 772180 |
Total Equity | 5683020 | 5331330 | 5323940 | 5238260 | 5173040 |
Common Stock | 1676260 | 1676260 | 1676260 | 1669120 | 1668140 |
Additional Paid-In Capital | 1708870 | 1697560 | 1686490 | 1682500 | 1688420 |
Retained Earnings (Accumulated Deficit) | 1479720 | 1466930 | 1551150 | 1503810 | 1509910 |
Treasury Stock - Common | -116007 | -91013 | -41037 | -42344 | -59552 |
Unrealized Gain (Loss) | 22068 | 31196 | 57646 | 41983 | |
Other Equity, Total | 912106 | 550395 | 451066 | 367516 | 324131 |
Total Liabilities & Shareholders’ Equity | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
Total Common Shares Outstanding | 1550.36 | 1557.49 | 1572.83 | 1568.66 | 1563.36 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | 230166 | 376171 | 44290 | 109014 | 186708 |
Efectivo de actividades de explotación | 1123100 | 1010930 | 670381 | 328301 | 399200 |
Efectivo de actividades de explotación | 583151 | 559671 | 583649 | 272446 | 182127 |
Partidas no monetarias | 252109 | 12308 | 172928 | 39061 | -43306 |
Cash Taxes Paid | 140423 | 201687 | 226768 | 44909 | 29883 |
Intereses pagados en efectivo | 108207 | 107350 | 127211 | 34914 | 8365 |
Cambios en el capital circulante | 57679 | 62781 | -130486 | -92220 | 73671 |
Efectivo de actividades de inversión | -198125 | 393530 | 292119 | -2835700 | -93342 |
Gastos de capital | -186037 | -236468 | -217710 | -134114 | -128262 |
Otras partidas de flujo de caja de inversión, total | -12088 | 629998 | 509829 | -2701580 | 34920 |
Efectivo procedente de actividades de financiación | -1070260 | -1088350 | -1005210 | 2946240 | -326226 |
Elementos de flujo de caja de financiación | -108592 | -142352 | -132804 | -71143 | -15099 |
Total Cash Dividends Paid | -283665 | -283357 | -282582 | -142952 | -141893 |
Emisión (retiro) de acciones, neto | -77531 | -2141 | -3737 | -1172 | -18756 |
Emisión (amortización) de deuda, neta | -600477 | -660504 | -586090 | 3161500 | -150478 |
Efectos del cambio de divisas | 28758 | 12501 | -21766 | -31269 | -4565 |
Variación neta de la tesorería | -116527 | 328608 | -64479 | 407571 | -24933 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 230166 | 241541 | 183721 | 137726 | 376171 |
Cash From Operating Activities | 1123100 | 747521 | 400011 | 166858 | 1010930 |
Cash From Operating Activities | 583151 | 430877 | 283595 | 142948 | 559671 |
Non-Cash Items | 252109 | 187026 | 112596 | 53003 | 12308 |
Cash Taxes Paid | 140423 | 101086 | 73872 | 35902 | 201687 |
Cash Interest Paid | 108207 | 84917 | 52668 | 23218 | 107350 |
Changes in Working Capital | 57679 | -111923 | -179901 | -166819 | 62781 |
Cash From Investing Activities | -198125 | -172487 | -103349 | -70445 | 393530 |
Capital Expenditures | -186037 | -134214 | -85783 | -42292 | -236468 |
Other Investing Cash Flow Items, Total | -12088 | -38273 | -17566 | -28153 | 629998 |
Cash From Financing Activities | -1070260 | -826465 | -658405 | -411038 | -1088350 |
Financing Cash Flow Items | -108592 | -85284 | -52681 | -23218 | -142352 |
Total Cash Dividends Paid | -283665 | -273024 | -141573 | -132032 | -283357 |
Issuance (Retirement) of Stock, Net | -77531 | -52538 | -2542 | -2542 | -2141 |
Issuance (Retirement) of Debt, Net | -600477 | -415619 | -461609 | -253246 | -660504 |
Foreign Exchange Effects | 28758 | 9549 | 3402 | 3324 | 12501 |
Net Change in Cash | -116527 | -241882 | -358341 | -311301 | 328608 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Nomura Asset Management Co., Ltd. | Investment Advisor | 4.1084 | 65007007 | -76000 | 2023-02-28 | LOW |
Sumitomo Mitsui Trust Asset Management Co., Ltd. | Investment Advisor | 3.8571 | 61030834 | 60935676 | 2022-11-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6684 | 42222686 | 45800 | 2023-02-28 | LOW |
JPMorgan Securities Japan Co., Ltd. | Research Firm | 2.3848 | 37735000 | 13609000 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2311 | 35302592 | -811008 | 2023-02-28 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.0544 | 32507000 | 2470629 | 2022-11-30 | LOW |
Daiwa Asset Management Co., Ltd. | Investment Advisor | 1.8823 | 29784238 | -48400 | 2023-02-28 | LOW |
Nippon Life Insurance Company | Insurance Company | 1.861 | 29447000 | -2377000 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 1.8554 | 29358500 | 18800 | 2023-01-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.5239 | 24113047 | 1171849 | 2022-12-31 | LOW |
Takeda Science Foundation | Corporation | 1.132 | 17912000 | 0 | 2022-09-30 | LOW |
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | Investment Advisor | 0.778 | 12309837 | -65791 | 2023-02-28 | LOW |
CPP Investment Board | Pension Fund | 0.7341 | 11616000 | 7985000 | 2022-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7089 | 11216737 | 13283 | 2023-02-28 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5202 | 8230678 | 143900 | 2023-02-28 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.5143 | 8137797 | 8137597 | 2021-06-30 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 0.4559 | 7213600 | 0 | 2023-01-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4421 | 6994953 | 16400 | 2023-02-28 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.4359 | 6897836 | -59516 | 2023-02-28 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4172 | 6601449 | 10924 | 2023-01-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Takeda Pharmaceutical Company Limited Company profile
Sobre Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited es una empresa con sede en Japón dedicada al negocio farmacéutico. La Compañía se dedica a la investigación, desarrollo, fabricación y venta de productos farmacéuticos, productos médicos generales, cuasi medicamentos productos sanitarios en Japón y en el extranjero. Las funciones de investigación y desarrollo de la Compañía se concentran en cuatro áreas oncología (cáncer), enfermedades del sistemas digestivo, enfermedades raras y neurología (enfermedades neuropsiquiatrías), así como dos unidades comerciales de productos de fraccionamiento de plasma y vacunas. La Compañía se dedica al mejora de tuberías en centro de investigación y desarrollo ubicados principalmente en Japón y Estados Unidos
- IndustriaPharmaceuticals (NEC)
- Dirección4F, 2-1-1, Nihombashihon-cho, CHUO-KU, TKY, Japan (JPN)
- Empleados47099
- CEOMasahiro Sakane
Industry: | Pharmaceuticals (NEC) |
4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com